Disseminated sepsis due to a Panton-Valentine leukocidin producing strain of community acquired meticillin resistant Staphylococcus aureus and use of intravenous immunoglobulin therapy

IVIG has been used for its anti-toxin effects in staphylococcal toxic shock syndrome (TSS) and other causes of septic shock. 4, 5 It was felt at this point that the potential benefit outweighed the risk of adverse events, so IVIG at a dose that might be used in TSS was administered (1 g/kg for two d...

Full description

Saved in:
Bibliographic Details
Published in:Archives of disease in childhood 2006-02, Vol.91 (2), p.201-201
Main Authors: Hampson, F G, Hancock, S W, Primhak, R A
Format: Article
Language:English
Subjects:
Adolescent
Antibiotics
Attrition (Research Studies)
Bacterial Toxins
Case studies
Causes of
Children
Community acquired meticillin resistant Staphylococcus aureus
Community Relations
Community-Acquired Infections - therapy
Complications and side effects
Diseases
Exotoxins
Health aspects
Humans
immunoglobulin therapy
Immunoglobulins
Immunoglobulins, Intravenous - therapeutic use
Intravenous immunoglobulins
Intravenous therapy
Laboratories
Letter
Leukocidins
Male
Methicillin Resistance
meticillin resistant Staphylococcus aureus
Mortality
Mortality Rate
Panton-Valentine leukocidin
Pediatric diseases
Pneumonia
Sepsis
Sepsis - therapy
Staphylococcal Infections - therapy
Staphylococcus aureus
Staphylococcus aureus - drug effects
Staphylococcus aureus - metabolism
Staphylococcus infections
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IVIG has been used for its anti-toxin effects in staphylococcal toxic shock syndrome (TSS) and other causes of septic shock. 4, 5 It was felt at this point that the potential benefit outweighed the risk of adverse events, so IVIG at a dose that might be used in TSS was administered (1 g/kg for two days.) This was followed by clinical improvement and a sustained fall in inflammatory markers.
ISSN:0003-9888
1468-2044
DOI:10.1136/adc.2005.075028